{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:02:04Z","timestamp":1785124924838,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["No. 232300421117 and No. 232102311149"],"award-info":[{"award-number":["No. 232300421117 and No. 232102311149"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Research and Development Joint Fund Project of Henan Province","award":["No. 245101610002 and No. 245101610009"],"award-info":[{"award-number":["No. 245101610002 and No. 245101610009"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["No. 2023YFF0714402"],"award-info":[{"award-number":["No. 2023YFF0714402"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03317-3","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:25:17Z","timestamp":1782912317000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Site-specific trastuzumab Fab-DM1 via butelase-1 with ABD fusion for potent HER2-positive tumor control"],"prefix":"10.1007","volume":"43","author":[{"given":"Yiming","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingwei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiudian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qisheng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziteng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangxue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoutao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"3317_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01536-y","volume":"8","author":"D Fan","year":"2023","unstructured":"Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T. Nanomedicine in cancer therapy. Sig Transduct Target Ther Nat Publishing Group. 2023;8:1\u201334. https:\/\/doi.org\/10.1038\/s41392-023-01536-y.","journal-title":"Sig Transduct Target Ther Nat Publishing Group"},{"key":"3317_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41578-020-00269-6","volume":"6","author":"MT Manzari","year":"2021","unstructured":"Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nat Rev Mater Nat Publishing Group. 2021;6:351\u201370. https:\/\/doi.org\/10.1038\/s41578-020-00269-6.","journal-title":"Nat Rev Mater Nat Publishing Group"},{"key":"3317_CR3","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jnci\/djz035","volume":"111","author":"MJ Birrer","year":"2019","unstructured":"Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-Drug Conjugate-Based Therapeutics: State of the Science. JNCI: J Natl Cancer Inst. 2019;111:538\u201349. https:\/\/doi.org\/10.1093\/jnci\/djz035.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"3317_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody\u2013drug conjugates for cancer therapy. Nat Rev Clin Oncol Nat Publishing Group. 2021;18:327\u201344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8.","journal-title":"Nat Rev Clin Oncol Nat Publishing Group"},{"key":"3317_CR5","doi-asserted-by":"publisher","first-page":"e0118977","DOI":"10.1371\/journal.pone.0118977","volume":"10","author":"C Vasalou","year":"2015","unstructured":"Vasalou C, Helmlinger G, Gomes B. A mechanistic tumor penetration model to guide antibody drug conjugate design. PLoS ONE. 2015;10:e0118977. https:\/\/doi.org\/10.1371\/journal.pone.0118977.","journal-title":"PLoS ONE"},{"key":"3317_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11095-021-03158-x","volume":"39","author":"M Aoyama","year":"2022","unstructured":"Aoyama M, Tada M, Yokoo H, Demizu Y, Ishii-Watabe A. Fc\u03b3 Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates. Pharm Res. 2022;39:89\u2013103. https:\/\/doi.org\/10.1007\/s11095-021-03158-x.","journal-title":"Pharm Res"},{"key":"3317_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/neuonc\/noac173","volume":"25","author":"AB Lassman","year":"2022","unstructured":"Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro Oncol. 2022;25:339\u201350. https:\/\/doi.org\/10.1093\/neuonc\/noac173.","journal-title":"Neuro Oncol"},{"key":"3317_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1158\/1535-7163.MCT-22-0440","volume":"22","author":"BM Bordeau","year":"2023","unstructured":"Bordeau BM, Nguyen TD, Polli JR, Chen P, Balthasar JP. Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody\u2013Drug Conjugates. Mol Cancer Ther Am Association Cancer Res. 2023;22:459\u201370. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0440.","journal-title":"Mol Cancer Ther Am Association Cancer Res"},{"key":"3317_CR9","doi-asserted-by":"publisher","unstructured":"Brennan FR, Polli JR, Sathish J, Ramones M, Wolf B, Schlothauer T, et al. Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies. mAbs. Taylor and Francis Ltd.; 2025. p. 17. https:\/\/doi.org\/10.1080\/19420862.2025.2505092.","DOI":"10.1080\/19420862.2025.2505092"},{"key":"3317_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41568-023-00637-8","volume":"24","author":"F Galvez-Cancino","year":"2024","unstructured":"Galvez-Cancino F, Simpson AP, Costoya C, Matos I, Qian D, Peggs KS, et al. Fc\u03b3 receptors and immunomodulatory antibodies in cancer. Nat Rev Cancer. 2024;24:51\u201371. https:\/\/doi.org\/10.1038\/s41568-023-00637-8.","journal-title":"Nat Rev Cancer"},{"key":"3317_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijbiomac.2021.02.103","volume":"177","author":"S Gao","year":"2021","unstructured":"Gao S, Rojas-Vega F, Rocha-Martin J, Guis\u00e1n JM. Oriented immobilization of antibodies through different surface regions containing amino groups: Selective immobilization through the bottom of the Fc region. Int J Biol Macromol. 2021;177:19\u201328. https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.02.103.","journal-title":"Int J Biol Macromol"},{"key":"3317_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.chembiol.2013.01.010","volume":"20","author":"P Strop","year":"2013","unstructured":"Strop P, Liu S-H, Dorywalska M, Delaria K, Dushin RG, Tran T-T, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013;20:161\u20137. https:\/\/doi.org\/10.1016\/j.chembiol.2013.01.010.","journal-title":"Chem Biol"},{"key":"3317_CR13","doi-asserted-by":"publisher","unstructured":"Zwaagstra JC, Sulea T, Baardsnes J, Radinovic S, Cepero-Donates Y, Robert A, et al. Binding and functional profiling of antibody mutants guides selection of optimal candidates as antibody drug conjugates. PLoS ONE. 2019;14. https:\/\/doi.org\/10.1371\/journal.pone.0226593.","DOI":"10.1371\/journal.pone.0226593"},{"key":"3317_CR14","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1039\/c7ob01027c","volume":"15","author":"Y Anami","year":"2017","unstructured":"Anami Y, Xiong W, Gui X, Deng M, Zhang CC, Zhang N, et al. Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency. Org Biomol Chem. 2017;15:5635\u201342. https:\/\/doi.org\/10.1039\/c7ob01027c.","journal-title":"Org Biomol Chem"},{"key":"3317_CR15","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1002\/tcr.202100054","volume":"21","author":"S Manabe","year":"2021","unstructured":"Manabe S, Yamaguchi Y. Antibody Glycoengineering and Homogeneous Antibody-Drug Conjugate Preparation. Chem Rec. 2021;21:3005\u201314. https:\/\/doi.org\/10.1002\/tcr.202100054.","journal-title":"Chem Rec"},{"key":"3317_CR16","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1021\/acs.molpharmaceut.5b00432","volume":"12","author":"CR Behrens","year":"2015","unstructured":"Behrens CR, Ha EH, Chinn LL, Bowers S, Probst G, Fitch-Bruhns M, et al. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs. Mol Pharm. 2015;12:3986\u201398. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00432.","journal-title":"Mol Pharm"},{"key":"3317_CR17","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1038\/nprot.2016.118","volume":"11","author":"GKT Nguyen","year":"2016","unstructured":"Nguyen GKT, Qiu Y, Cao Y, Hemu X, Liu C-F, Tam JP. Butelase-mediated cyclization and ligation of peptides and proteins. Nat Protoc. 2016;11:1977\u201388. https:\/\/doi.org\/10.1038\/nprot.2016.118.","journal-title":"Nat Protoc"},{"key":"3317_CR18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nchembio.1586","volume":"10","author":"GKT Nguyen","year":"2014","unstructured":"Nguyen GKT, Wang S, Qiu Y, Hemu X, Lian Y, Tam JP. Butelase 1 is an Asx-specific ligase enabling peptide macrocyclization and synthesis. Nat Chem Biol Nat Publishing Group. 2014;10:732\u20138. https:\/\/doi.org\/10.1038\/nchembio.1586.","journal-title":"Nat Chem Biol Nat Publishing Group"},{"key":"3317_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","volume":"146","author":"H-H Peter","year":"2020","unstructured":"Peter H-H, Ochs HD, Cunningham-Rundles C, Vinh DC, Kiessling P, Greve B, et al. Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations. J Allergy Clin Immunol. 2020;146:479\u2013e4915. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.016.","journal-title":"J Allergy Clin Immunol"},{"key":"3317_CR20","doi-asserted-by":"publisher","first-page":"9489","DOI":"10.3390\/ijms22179489","volume":"22","author":"J Kim","year":"2021","unstructured":"Kim J, Lee JY, Kim HG, Kwak MW, Kang TH. Fc Receptor Variants and Disease: A Crucial Factor to Consider in the Antibody Therapeutics in Clinic. Int J Mol Sci. 2021;22:9489. https:\/\/doi.org\/10.3390\/ijms22179489.","journal-title":"Int J Mol Sci"},{"key":"3317_CR21","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2174\/1381612821666150302120047","volume":"21","author":"B Rogers","year":"2015","unstructured":"Rogers B, Dong D, Li Z, Li Z. Recombinant human serum albumin fusion proteins and novel applications in drug delivery and therapy. Curr Pharm Des. 2015;21:1899\u2013907. https:\/\/doi.org\/10.2174\/1381612821666150302120047.","journal-title":"Curr Pharm Des"},{"key":"3317_CR22","doi-asserted-by":"publisher","unstructured":"Qiao S-W, Kobayashi K, Johansen F-E, Sollid LM, Andersen JT, Milford E et al. Dependence of antibody-mediated presentation of antigen on FcRn. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences; 2008;105:9337\u201342. https:\/\/doi.org\/10.1073\/pnas.0801717105","DOI":"10.1073\/pnas.0801717105"},{"key":"3317_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.xphs.2019.08.006","volume":"109","author":"JW Buecheler","year":"2020","unstructured":"Buecheler JW, Winzer M, Weber C, Gieseler H. Alteration of Physicochemical Properties for Antibody-Drug Conjugates and Their Impact on Stability. J Pharm Sci. 2020;109:161\u20138. https:\/\/doi.org\/10.1016\/j.xphs.2019.08.006.","journal-title":"J Pharm Sci"},{"key":"3317_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4161\/19420862.2014.985522","volume":"7","author":"CT Mendler","year":"2015","unstructured":"Mendler CT, Friedrich L, Laitinen I, Schlapschy M, Schwaiger M, Wester H-J, et al. High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation. MAbs. 2015;7:96\u2013109. https:\/\/doi.org\/10.4161\/19420862.2014.985522.","journal-title":"MAbs"},{"key":"3317_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jconrel.2015.10.038","volume":"240","author":"VN Podust","year":"2016","unstructured":"Podust VN, Balan S, Sim B-C, Coyle MP, Ernst U, Peters RT, et al. Extension of in vivo half-life of biologically active molecules by XTEN protein polymers. J Control Release. 2016;240:52\u201366. https:\/\/doi.org\/10.1016\/j.jconrel.2015.10.038.","journal-title":"J Control Release"},{"key":"3317_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10965-023-03823-2","volume":"30","author":"B Jia","year":"2023","unstructured":"Jia B, Sun W, Duan W, Ma X, Wang Y, Zhou C, et al. Fully biodegradable self-healing hydrogel prepared based on poly(aspartic acid) and pectin for drug delivery and anti-tumor therapy. J Polym Res. 2023;30:453. https:\/\/doi.org\/10.1007\/s10965-023-03823-2.","journal-title":"J Polym Res"},{"key":"3317_CR27","doi-asserted-by":"publisher","first-page":"102915","DOI":"10.1016\/j.jddst.2021.102915","volume":"66","author":"AK Nayak","year":"2021","unstructured":"Nayak AK, Hasnain MS, Aminabhavi TM. Drug delivery using interpenetrating polymeric networks of natural polymers: a recent update. J Drug Delivery Sci Technol. 2021;66:102915. https:\/\/doi.org\/10.1016\/j.jddst.2021.102915.","journal-title":"J Drug Delivery Sci Technol"},{"key":"3317_CR28","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1002\/cncr.25120","volume":"116","author":"HR Chang","year":"2010","unstructured":"Chang HR. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer. 2010;116:2856\u201367. https:\/\/doi.org\/10.1002\/cncr.25120.","journal-title":"Cancer"},{"key":"3317_CR29","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","volume":"68","author":"GD Lewis Phillips","year":"2008","unstructured":"Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody\u2013Cytotoxic Drug Conjugate. Cancer Res. 2008;68:9280\u201390. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1776.","journal-title":"Cancer Res"},{"key":"3317_CR30","doi-asserted-by":"publisher","first-page":"e1804452","DOI":"10.1002\/smll.201804452","volume":"15","author":"P Yousefpour","year":"2019","unstructured":"Yousefpour P, Ahn L, Tewksbury J, Saha S, Costa SA, Bellucci JJ, et al. Conjugate of Doxorubicin to Albumin-Binding Peptide Outperforms Aldoxorubicin. Small. 2019;15:e1804452. https:\/\/doi.org\/10.1002\/smll.201804452.","journal-title":"Small"},{"key":"3317_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21:203\u201323. https:\/\/doi.org\/10.1038\/s41571-023-00850-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"3317_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.bios.2015.03.032","volume":"70","author":"V Crivianu-Gaita","year":"2015","unstructured":"Crivianu-Gaita V, Thompson M. Immobilization of Fab\u2019 fragments onto substrate surfaces: A survey of methods and applications. Biosens Bioelectron. 2015;70:167\u201380. https:\/\/doi.org\/10.1016\/j.bios.2015.03.032.","journal-title":"Biosens Bioelectron"},{"key":"3317_CR33","doi-asserted-by":"publisher","first-page":"133933","DOI":"10.1016\/j.ijbiomac.2024.133933","volume":"276","author":"J Zhao","year":"2024","unstructured":"Zhao J, Song W, Huang Z, Yuan X, Huang Y, Hou Y, et al. Top-down overexpression optimization of butelase-1 in Escherichia coli and its application in anti-tumor peptides. Int J Biol Macromol. 2024;276:133933. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.133933.","journal-title":"Int J Biol Macromol"},{"key":"3317_CR34","doi-asserted-by":"publisher","first-page":"23105","DOI":"10.1039\/d1ra03763c","volume":"11","author":"X Hemu","year":"2021","unstructured":"Hemu X, Zhang X, Nguyen GKT, To J, Serra A, Loo S, et al. Characterization and application of natural and recombinant butelase-1 to improve industrial enzymes by end-to-end circularization. RSC Adv. 2021;11:23105\u201312. https:\/\/doi.org\/10.1039\/d1ra03763c.","journal-title":"RSC Adv"},{"key":"3317_CR35","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1002\/anie.201208292","volume":"52","author":"JJ Bellucci","year":"2013","unstructured":"Bellucci JJ, Amiram M, Bhattacharyya J, McCafferty D, Chilkoti A. Three-in-one chromatography-free purification, tag removal, and site-specific modification of recombinant fusion proteins using sortase A and elastin-like polypeptides. Angew Chem Int Ed Engl. 2013;52:3703\u20138. https:\/\/doi.org\/10.1002\/anie.201208292.","journal-title":"Angew Chem Int Ed Engl"},{"key":"3317_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jbiotec.2019.06.299","volume":"302","author":"A Caporale","year":"2019","unstructured":"Caporale A, Monti A, Selis F, Sandomenico A, Tonon G, Ruvo M, et al. A comparative analysis of catalytic activity and stability of microbial transglutaminase in controlled denaturing conditions. J Biotechnol. 2019;302:48\u201357. https:\/\/doi.org\/10.1016\/j.jbiotec.2019.06.299.","journal-title":"J Biotechnol"},{"key":"3317_CR37","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1021\/acs.bioconjchem.8b00563","volume":"29","author":"TJ Harmand","year":"2018","unstructured":"Harmand TJ, Bousbaine D, Chan A, Zhang X, Liu DR, Tam JP, et al. One-Pot Dual Labeling of IgG 1 and Preparation of C-to-C Fusion Proteins Through a Combination of Sortase A and Butelase 1. Bioconjug Chem. 2018;29:3245\u20139. https:\/\/doi.org\/10.1021\/acs.bioconjchem.8b00563.","journal-title":"Bioconjug Chem"},{"key":"3317_CR38","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1021\/acs.bioconjchem.6b00538","volume":"27","author":"Y Cao","year":"2016","unstructured":"Cao Y, Nguyen GKT, Chuah S, Tam JP, Liu C-F. Butelase-mediated ligation as an efficient bioconjugation method for the synthesis of peptide dendrimers. Bioconjug Chem. 2016;27:2592\u20136. https:\/\/doi.org\/10.1021\/acs.bioconjchem.6b00538.","journal-title":"Bioconjug Chem"},{"key":"3317_CR39","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1038\/s12276-022-00870-5","volume":"54","author":"S Ko","year":"2022","unstructured":"Ko S, Park S, Sohn MH, Jo M, Ko BJ, Na J-H, et al. An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies. Exp Mol Med. 2022;54:1850\u201361. https:\/\/doi.org\/10.1038\/s12276-022-00870-5.","journal-title":"Exp Mol Med"},{"key":"3317_CR40","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jconrel.2021.07.007","volume":"337","author":"I Rudnik-Jansen","year":"2021","unstructured":"Rudnik-Jansen I, Howard KA. FcRn expression in cancer: Mechanistic basis and therapeutic opportunities. J Control Release. 2021;337:248\u201357. https:\/\/doi.org\/10.1016\/j.jconrel.2021.07.007.","journal-title":"J Control Release"},{"key":"3317_CR41","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1074\/mcp.M114.042044","volume":"14","author":"PF Jensen","year":"2015","unstructured":"Jensen PF, Larraillet V, Schlothauer T, Kettenberger H, Hilger M, Rand KD. Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen\/deuterium exchange mass spectrometry. Mol Cell Proteom. 2015;14:148\u201361. https:\/\/doi.org\/10.1074\/mcp.M114.042044.","journal-title":"Mol Cell Proteom"},{"key":"3317_CR42","doi-asserted-by":"publisher","first-page":"1802135","DOI":"10.1080\/19420862.2020.1802135","volume":"12","author":"Y Sun","year":"2020","unstructured":"Sun Y, Estevez A, Schlothauer T, Wecksler AT. Antigen physiochemical properties allosterically effect the IgG Fc-region and Fc neonatal receptor affinity. MAbs. 2020;12:1802135. https:\/\/doi.org\/10.1080\/19420862.2020.1802135.","journal-title":"MAbs"},{"key":"3317_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.tibtech.2014.11.001","volume":"33","author":"D Levin","year":"2015","unstructured":"Levin D, Golding B, Strome SE, Sauna ZE. Fc fusion as a platform technology: potential for modulating immunogenicity. Trends Biotechnol. 2015;33:27\u201334. https:\/\/doi.org\/10.1016\/j.tibtech.2014.11.001.","journal-title":"Trends Biotechnol"},{"key":"3317_CR44","doi-asserted-by":"publisher","first-page":"173650","DOI":"10.1016\/j.ejphar.2020.173650","volume":"890","author":"H Tan","year":"2021","unstructured":"Tan H, Su W, Zhang W, Zhang J, Sattler M, Zou P. Albumin-binding domain extends half-life of glucagon-like peptide-1. Eur J Pharmacol. 2021;890:173650. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173650.","journal-title":"Eur J Pharmacol"},{"key":"3317_CR45","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/protein\/gzn028","volume":"21","author":"A Jonsson","year":"2008","unstructured":"Jonsson A, Dogan J, Herne N, Abrahms\u00e9n L, Nygren P-A. Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng Des Sel. 2008;21:515\u201327. https:\/\/doi.org\/10.1093\/protein\/gzn028.","journal-title":"Protein Eng Des Sel"},{"key":"3317_CR46","doi-asserted-by":"publisher","first-page":"174152","DOI":"10.1016\/j.ejphar.2021.174152","volume":"904","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Qian M, Wu Y, Wang Y, Shangguan W, Lu J, et al. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain. Eur J Pharmacol. 2021;904:174152. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174152.","journal-title":"Eur J Pharmacol"},{"key":"3317_CR47","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","volume":"66","author":"HK Erickson","year":"2006","unstructured":"Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66:4426\u201333. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4489.","journal-title":"Cancer Res"},{"key":"3317_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40591-016-0048-8","volume":"4","author":"MT Larsen","year":"2016","unstructured":"Larsen MT, Kuhlmann M, Hvam ML, Howard KA. Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther. 2016;4:3. https:\/\/doi.org\/10.1186\/s40591-016-0048-8.","journal-title":"Mol Cell Ther"},{"key":"3317_CR49","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nbt.3212","volume":"33","author":"RP Lyon","year":"2015","unstructured":"Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 2015;33:733\u20135. https:\/\/doi.org\/10.1038\/nbt.3212.","journal-title":"Nat Biotechnol"},{"key":"3317_CR50","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315\u201337. https:\/\/doi.org\/10.1038\/nrd.2016.268.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03317-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03317-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03317-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T03:46:43Z","timestamp":1785124003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03317-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["3317"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03317-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were performed in accordance with national guidelines and approved by the Ethics Committee of Zhengzhou University (ethics approval number: ZZUIRB2025-103).","order":4,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"209"}}